Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice

Neuroscience

Volumn 285, Issue , 2015, Pages 281-291

  Wang, W ^a,b,c   Lu, Y ^c   Xue, Z ^c   Li, C ^c   Wang, C ^c   Zhao, X ^c   Zhang, J ^c   Wei, X ^c   Chen, X ^c   Cui, W ^c   Wang, Q ^c   Zhou, W ^c  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Cancer Hospital   (China)

^c NINGBO UNIVERSITY   (China)

Author keywords

Acetyl l carnitine; Brain derived neurotrophic factor; Depression; Neuropeptide VGF; Phosphatidylinositol 3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BRAIN DERIVED NEUROTROPHIC FACTOR; LEVACECARNINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ACETYLCARNITINE; ANTIDEPRESSANT AGENT; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; NEUROPEPTIDE; VGF PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOWN REGULATION; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FORCED SWIM TEST; HIPPOCAMPUS; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; MENTAL STRESS; METABOLISM; PHOSPHORYLATION; TIME;

ACETYLCARNITINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHROMONES; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HIPPOCAMPUS; MALE; MICE; MORPHOLINES; NEUROPEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 84916879874     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.11.025     Document Type: Article

References (56)

1. Adell A., Castro E., Celada P., Bortolozzi A., Pazos A., Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005, 10:578-585.
2. Adlard P.A., Cotman C.W. Voluntary exercise protects against stress-induced decreases in brain-derived neurotrophic factor protein expression. Neuroscience 2004, 124:985-992.
3. Astle M.V., Ooms L.M., Cole A.R., Binge L.C., Dyson J.M., Layton M.J., Petratos S., Sutherland C., Mitchell C.A. Identification of a proline-rich inositol polyphosphate 5-phosphatase (PIPP)·collapsin response mediator protein 2 (CRMP2) complex that regulates neurite elongation. J Biol Chem 2011, 286:23407-23418.
4. Bersani G., Meco G., Denaro A., Liberati D., Colletti C., Nicolai R., Bersani F.S., Koverech A. l-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 2013, 23:1219-1225.
5. Brennan B.P., Jensen J.E., Hudson J.I., Coit C.E., Beaulieu A., Pope H.G., Renshaw P.F., Cohen B.M. A placebo-controlled trial of acetyl-l-carnitine and α-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol 2013, 33:627-635.
6. Chan C.B., Liu X., Pradoldej S., Hao C., An J., Yepes M., Luo H.R., Ye K. Phosphoinositide 3-kinase enhancer regulates neuronal dendritogenesis and survival in neocortex. J Neurosci 2011, 31:8083-8092.
7. Chaki S., Ago Y., Palucha-Paniewiera A., Matrisciano F., Pilc A. MGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013, 66:40-52.
8. Chen L., Xing T., Wang M., Miao Y., Tang M., Chen J., Li G., Ruan D.Y. Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur J Neurosci 2011, 33:266-275.
9. Castrén E. Is mood chemistry?. Nat Rev Neurosci 2005, 6:241-246.
10. Cattaneo A., Sesta A., Calabrese F., Nielsen G., Riva M.A., Gennarelli M. The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 2010, 35:1423-1428.
11. Cuccurazzu B., Bortolotto V., Valente M.M., Ubezio F., Koverech A., Canonico P.L., Grilli M. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-l-carnitine. Neuropsychopharmacology 2013, 38:2220-2230.
12. Dranovsky A., Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 2006, 59:1136-1143.
13. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
14. Duman R.S., Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012, 35:47-56.
15. Ghasemi T., Abnous K., Vahdati F., Mehri S., Razavi B.M., Hosseinzadeh H. Antidepressant effect of Crocus sativus aqueous extract and its effect on CREB, BDNF, and VGF transcript and protein levels in rat hippocampus. Drug Res (Stuttg) 2014, [2014 Apr 2, Epub ahead of print, PMID: 24696423].
16. Jones L.L., McDonald D.A., Borum P.R. Acylcarnitines: role in brain. Prog Lipid Res 2010, 49:61-75.
17. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105. National Comorbidity Survey Replication.
18. Kido Y., Tamai I., Ohnari A., Sai Y., Kagami T., Nezu J., Nikaido H., Hashimoto N., Asano M., Tsuji A. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 2001, 79:959-969.
19. Kitagishi Y., Kobayashi M., Kikuta K., Matsuda S. Roles of PI3K/AKT/GSK3/mTOR pathway in cell signaling of mental illnesses. Depress Res Treat 2012, 2012:752563.
20. Kocsis K., Knapp L., Gellért L., Oláh G., Kis Z., Takakuwa H., Iwamori N., Ono E., Toldi J., Farkas T. Acetyl-l-carnitine normalizes the impaired long-term potentiation and spine density in a rat model of global ischemia. Neuroscience 2014, 269:265-272.
21. Laske C., Banschbach S., Stransky E., Bosch S., Straten G., Machann J., Fritsche A., Hipp A., Niess A., Eschweiler G.W. Exercise-induced normalization of decreased BDNF serum concentration in elderly women with remitted major depression. Int J Neuropsychopharmacol 2010, 13:595-602.
22. Leibrock C., Ackermann T.F., Hierlmeier M., Lang F., Borgwardt S., Lang U.E. Akt2 deficiency is associated with anxiety and depressive behavior in mice. Cell Physiol Biochem 2013, 32:766-777.
23. Licinio J., Wong M.L. The pharmacogenomics of depression. Pharmacogenomics J 2001, 1:175-177.
24. Lin P., Wang C., Xu B., Gao S., Guo J., Zhao X., Huang H., Zhang J., Chen X., Wang Q., Zhou W. The VGF-derived peptide TLQP62 produces antidepressant-like effects in mice via the BDNF/TrkB/CREB signaling pathway. Pharmacol Biochem Behav 2014, 120:140-148.
25. Lindholm J.S., Castrén E. Mice with altered BDNF signaling as models for mood disorders and antidepressant effects. Front Behav Neurosci 2014, 8:143.
26. Lu L., Uejima J.L., Gray S.M., Bossert J.M., Shaham Y. Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol Psychiatry 2007, 61:591-598.
27. Machado-Vieira R., Salvadore G., Luckenbaugh D.A., Manji H.K., Zarate C.A. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008, 69:946-958.
28. MacQueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 2011, 16:252-264.
29. Marosi K., Mattson M.P. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol Metab 2014, 25:89-98.
30. Massart R., Mongeau R., Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 2012, 367:2485-2494.
31. Moretti M., Budni J., Freitas A.E., Rosa P.B., Rodrigues A.L. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway. J Psychiatr Res 2014, 48:16-24.
32. Muguruza C., Miranda-Azpiazu P., Díez-Alarcia R., Morentin B., González-Maeso J., Callado L.F., Meana J.J. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment. Neuropharmacology 2014, 86C:311-318.
33. Nasca C., Xenos D., Barone Y., Caruso A., Scaccianoce S., Matrisciano F., Battaglia G., Mathé A.A., Pittaluga A., Lionetto L., Simmaco M., Nicoletti F. l-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 2013, 110:4804-4809.
34. Nedachi T., Kawai T., Matsuwaki T., Yamanouchi K., Nishihara M. Progranulin enhances neural progenitor cell proliferation through glycogen synthase kinase 3β phosphorylation. Neuroscience 2011, 185:106-115.
35. Numakawa T., Adachi N., Richards M., Chiba S., Kunugi H. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 2013, 239:157-172.
36. Pizzorusso T., Ratto G.M., Putignano E., Maffei L. Brain-derived neurotrophic factor causes cAMP response element-binding protein phosphorylation in absence of calcium increases in slices and cultured neurons from rat visual cortex. J Neurosci 2000, 20:2809-2816.
37. Pulvirenti G., Valerio C., Spadaro F., D'Agata V., Freni V., Nardo L., Drago F. Acetylcarnitine reduces the immobility of rats in a despair test (constrained swim). Behav Neural Biol 1990, 54:110-114.
38. Rodgers E.E., Theibert A.B. Functions of PI 3-kinase in development of the nervous system. Int J Dev Neurosci 2002, 20:187-197.
39. Russo-Neustadt A., Beard R.C., Cotman C.W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999, 21:679-682.
40. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., Takimoto-Kimura R., Kleschevnikov A.M., Sambamurti K., Chung P.P., Xia W., Villar A., Campbell W.A., Kulnane L.S., Nixon R.A., Lamb B.T., Epstein C.J., Stokin G.B., Goldstein L.S., Mobley W.C. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
41. Sarkisyan G., Roberts A.J., Hedlund P.B. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 2010, 209:99-108.
42. Schaevitz L.R., Nicolai R., Lopez C.M., D'Iddio S., Iannoni E., Berger-Sweeney J.E. Acetyl-l-carnitine improves behavior and dendritic morphology in a mouse model of Rett syndrome. PLoS One 2012, 7:e51586.
43. Shi H.S., Zhu W.L., Liu J.F., Luo Y.X., Si J.J., Wang S.J., Xue Y.X., Ding Z.B., Shi J., Lu L. PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. Neuropsychopharmacology 2012, 37:2671-2683.
44. Smeland O.B., Meisingset T.W., Borges K., Sonnewald U. Chronic acetyl-l-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem Int 2012, 61:100-107.
45. Tempesta E., Janiri L., Pirrongelli C. Stereospecific effects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine and serotonin. Neuropharmacology 1985, 24:43-50.
46. Thakker-Varia S., Krol J.J., Nettleton J., Bilimoria P.M., Bangasser D.A., Shors T.J., Black I.B., Alder J. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci 2007, 27:12156-12167.
47. Thakker-Varia S., Alder J. Neuropeptides in depression: role of VGF. Behav Brain Res 2009, 197:262-278.
48. Thakker-Varia S., Jean Y.Y., Parikh P., Sizer C.F., Jernstedt Ayer J., Parikh A., Hyde T.M., Buyske S., Alder J. The neuropeptide VGF is reduced in human bipolar postmortem brain and contributes to some of the behavioral and molecular effects of lithium. J Neurosci 2010, 30:9368-9380.
49. Vahdati Hassani F., Naseri V., Razavi B.M., Mehri S., Abnous K., Hosseinzadeh H. Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus. Daru 2014, 22:16.
50. van den Pol A.N., Bina K., Decavel C., Ghosh P. VGF expression in the brain. J Comp Neurol 1994, 347:455-469.
51. van den Pol A.N., Decavel C., Levi A., Paterson B. Hypothalamic expression of a novel gene product, VGF: immunocytochemical analysis. J Neurosci 1989, 9:4122-4137.
52. Vivoli E., Di Cesare Mannelli L., Salvicchi A., Bartolini A., Koverech A., Nicolai R., Benatti P., Ghelardini C. Acetyl-l-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience 2010, 167:1168-1174.
53. Wang C., Zhang J., Lu Y., Lin P., Pan T., Zhao X., Liu A., Wang Q., Zhou W., Zhang H.T. Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice. Metab Brain Dis 2014, 10.1007/s11011-014-9533-4.
54. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
55. Xu Y., Pan J., Chen L., Zhang C., Sun J., Li J., Nguyen L., Nair N., Zhang H., O'Donnell J.M. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway. Int J Neuropsychopharmacol 2013, 16:835-847.
56. Zhang J., Guo J., Zhao X., Chen Z., Wang G., Liu A., Wang Q., Zhou W., Xu Y., Wang C. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 2013, 250:230-237.